CG-P5 peptide is under clinical development by Caregen and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CG-P5 peptide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CG-P5 peptide overview
The drug candidate is under development for the treatment of wet macular degeneration. It is administered through ophthalmic route as drops.
Caregen overview
Caregen is a research and development-based skin biology company. The company involves in the manufacturing and marketing of biomimetic peptides and growth factors. Caregen offers anti-aging, anti-pigmentation, hair growth, anti-inflammation, skin trouble care, lipolysis and oral care biomimetic peptides. The company serves applications to cosmeceutical, class III medical devices, food supplements, and pharmaceutical industries. Its growth factors are used for anti-wrinkle, skin lifting, hair growth and skin firming among others. Caregen is headquartered in Anyang-si, South Korea.
For a complete picture of CG-P5 peptide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
